Find a Study

Alexander Disease| ION373

.714.

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD)

This is a Phase 1-3, multi-center, double-blind, placebo-controlled, multiple-ascending dose (MAD) study in up to 58 patients with AxD. Participants will be randomized in a 2:1 ratio to receive ION373 or matching placebo for a 60-week double-blind treatment period; then all participants will receive ION373 for a 60-week open-label treatment period.

Purpose of Study

The purpose of this study is to evaluate the safety and efficacy of ION373 in improving or stabilizing gross motor function across the full range of affected domains in patients with AxD.

Eligibility

Age:
2 - 65
Sex:
Female Icon + Male Icon

Key Inclusion / Exclusion Criteria

Inclusion Criteria:

  • Clinical phenotype and brain imaging consistent with a diagnosis of Alexander disease
  • Documented genetic mutation in the GFAP gene
  • Aged ≥ 2 to 65 years old at the time of informed consent
  • Able and willing to meet all study requirements, including travel to Study Center, procedures, measurements and visits
  • Patients < 18 years old at Screening must have a trial partner (parent, caregiver or other)

Exclusion Criteria:

  • Clinically significant abnormalities in medical history or physical examination
  • Any clinically significant laboratory abnormalities that would render a patient unsuitable for inclusion
  • Any contraindication or unwillingness to undergo MRI
  • Treatment with another investigational drug, biological agent, or device within 1 month of Screening, or 5 half-lives of investigational agent, whichever is longer; concurrent participation in any other clinical study (including observational and non-interventional studies)
  • Previous treatment with an oligonucleotide (including small interfering ribonucleic acid [siRNA]) within 4 months of Screening if single dose received, or within 12 months of Screening if multiple doses received. This exclusion does not apply to vaccines (both messenger ribonucleic acid [mRNA] and viral vector vaccines).
  • History of gene therapy or cell transplantation or any other experimental brain surgery [ROW]
  • Obstructive hydrocephalus
  • Presence of a functional ventriculoperitoneal shunt for the drainage of cerebrospinal fluid (CSF) or an implanted central nervous system (CNS) catheter
  • Known brain or spinal disease that would interfere with the lumbar puncture (LP) process, CSF circulation or safety assessment.
  • Hospitalization for any major medical or surgical procedure involving general anesthesia within 12 weeks prior to Screening or planned during the study
  • Have any other conditions, which, in the opinion of the Investigator would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study

Conditions:

Alexander Disease

Status:

Recruiting

Phase:

Phase 3

Clinical Trials ID

NCT04849741

Read Detailed Summary:

Start Date / End Date:

06 2021 - 11 2025

Intervention:

ION373

Enrollment:

73

Full Details:

https://clinicaltrials.gov/ct2/show/NCT04849741

32 Study Locations

United States











Canada





Netherlands


Australia


Israel




Italy






United Kingdom







Japan



Study Locations Map: